摘要
目的观察含培门冬酶注射液的VDPAP方案诱导治疗儿童急性淋巴细胞白血病(ALL)的远期疗效。方法选择初发ALL患儿,随机分成两组:试验组采用含国产培门冬酶注射液的VDPAP方案诱导治疗,对照组采用含左旋门冬酰胺酶(L-Asp)的VDLP方案。统计一疗程完全缓解(CR)率,并采用Kaplan-Meier法评估患儿的总生存(OS)率及疾病无进展生存(PFS)率,组间差异用Log-rank检验。结果入组患儿51例,可评估疗效者46例,其中试验组27例,CR率为96%,总有效率为96%;对照组19例,CR率为95%,总有效率为100%,两组间差异无统计学意义。试验组3年预计OS率为(78.8±8.4)%,5年预计OS率为(68.9±11.8)%;对照组3年预计OS率为(88.9±7.4)%,5年预计OS率为(82.1±9.5)%,两组间差异无统计学意义。试验组3年预计PFS率为(74.1±9.1)%,5年预计PFS率为(63.5±12.5)%;对照组3年预计PFS率为(83.3±8.8)%,5年预计PFS率为(77.8±9.8)%,两组间差异无统计学意义。结论含培门冬酶的VDPAP方案与含L-Asp的VDLP方案诱导治疗儿童ALL,其CR率及远期疗效相似,可以作为儿童ALL的一线治疗方案。
Objective To evaluate the long-term efficacy of VDPAP induction regimen containing PEG-Asp in newly diagnosed childhood acute lymphoblastic leukemia（ALL）.Methods Fifty one children with newly diagnosed ALL were randomized to two groups： the test group received PEG-Asp-containing VDPAP regimen,and the control group received L-asparaginase（L-asp）-containing VDLP regimen for induction therapy.The complete remission（CR） rate was observed.Kaplan-Meier method was used to evaluate the overall survival（OS） rate and progress free survival（PFS） rate.The differences between two groups were analyzed by 2-sided log-rank test.Results Both CR rate and total effective rate in test group were 96%,compared with 95% and 100% in control group respectively.There was no statistical significance in two groups（P0.05）.The estimated 3-year OS rates were（78.8±8.4）% and（88.9±7.4）%,5-year OS rates were（68.9±11.8）% and（82.1±9.5）%,the estimated 3-year PFS rates were（74.1±9.1）% and（83.3±8.8）%,5-year PFS rates were（63.5±12.5）% and（77.8±9.8）%（P0.05） in test and control groups,respectively.There was no statistical significance in two groups（P0.05）.Conclusion The effectiveness of PEG-Asp and L-asp for treatment of pediatric ALL is similar.PEG-Asp could be used as the first-line treatment in pediatric ALL.
出处
《中国小儿血液与肿瘤杂志》
CAS
2010年第6期254-257,共4页
Journal of China Pediatric Blood and Cancer
关键词
培门冬酶
白血病
淋巴细胞
急性
儿童
疗效
PEG-Asp
Leukemia
lymphoblastic
acute
Child
ProsteFJtive efficacy
